Pliant Therapeutics Q3 net loss narrows to $26.3 mln

Reuters11-07

Pliant <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss narrows to $26.3 mln

Overview

Pliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuation
Company completed voluntary prepayment of Oxford Finance loan

Outlook

BEACON-IPF close out activities to be completed in Q4 2025

Result Drivers

R&D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trial
ADMINISTRATIVE COSTS - Decline due to strategic workforce restructuring

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$26.30 mln
Q3 Operating Expenses		-$28.27 mln
Q3 Operating Income		-$28.27 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 45.3% above its November 5 closing price of $1.64

Press Release: ID:nGNX8287tf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581454440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581454440","market":"us","top_or_hot":-1,"title":"Pliant Therapeutics Q3 net loss narrows to $26.3 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $26.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuation</p></li><li><p>Company completed voluntary prepayment of Oxford Finance loan</p></li></ul><p><span>Outlook</span></p><ul><li><p>BEACON-IPF close out activities to be completed in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trial</p></li><li><p>ADMINISTRATIVE COSTS - Decline due to strategic workforce restructuring</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>-$28.27 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$28.27 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 45.3% above its November 5 closing price of $1.64</p></li></ul><p>Press Release: <span>ID:nGNX8287tf</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics Q3 net loss narrows to $26.3 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics Q3 net loss narrows to $26.3 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $26.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Pliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuation</p></li><li><p>Company completed voluntary prepayment of Oxford Finance loan</p></li></ul><p><span>Outlook</span></p><ul><li><p>BEACON-IPF close out activities to be completed in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trial</p></li><li><p>ADMINISTRATIVE COSTS - Decline due to strategic workforce restructuring</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$26.30 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>-$28.27 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$28.27 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 45.3% above its November 5 closing price of $1.64</p></li></ul><p>Press Release: <span>ID:nGNX8287tf</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1JK:1","article_id":"2581454440","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581454440","pubTimestamp":1762465936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pliant Therapeutics Q3 net loss narrows to $26.3 mlnOverviewPliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuationCompany completed voluntary prepayment of Oxford Finance loanOu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PLRX":"Pliant Therapeutics, Inc."},"translate_title":"Pliant Therapeutics第三季度净亏损收窄至2630万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRX":0.9},"content_text":"Pliant Therapeutics Q3 net loss narrows to $26.3 mlnOverviewPliant Q3 net loss narrows to $26.3 mln, driven by BEACON-IPF discontinuationCompany completed voluntary prepayment of Oxford Finance loanOutlookBEACON-IPF close out activities to be completed in Q4 2025Result DriversR&D EXPENSES - Decrease primarily due to discontinuation of BEACON-IPF trialADMINISTRATIVE COSTS - Decline due to strategic workforce restructuringKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$26.30 mlnQ3 Operating Expenses-$28.27 mlnQ3 Operating Income-$28.27 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 6 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 45.3% above its November 5 closing price of $1.64Press Release: ID:nGNX8287tfFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581454440","isCrawlerRequest":true}